BioSpace News Archive

Business

Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second quarter 2022 financial results on Wednesday, August 3rd, 2022 at 8:00 a.m. ET.

July 20, 2022
·
2 min read
BioMidwest

Colorado State University College of Veterinary Medicine and Biomedical Sciences Acquires Second SRT System from Sensus Healthcare

Sensus Healthcare, Inc. announces the expansion of its relationship with Colorado State University College of Veterinary Medicine and Biomedical Studies with the acquisition of a second SRT-100™ system by CSU.

July 20, 2022
·
5 min read
Business

Auron Therapeutics announces $48 million Series A financing to drive novel oncology pipeline leveraging a machine learning, multi-omics-based platform

Auron Therapeutics, a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer, announced the completion of its $48 million Series A financing round.

July 20, 2022
·
3 min read
Business

MIMEDX to Host Second Quarter 2022 Operating and Financial Results Conference Call on August 3

MiMedx Group, Inc., a transformational placental biologics company, announced that it will report operating and financial results for the second quarter ended June 30, 2022, after the market close on Tuesday, August 2, 2022.

July 20, 2022
·
1 min read
Spectral Medical Provides Update on Tigris Clinical Trial

Spectral Medical Inc. today provided a clinical trial update on Tigris, a follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

July 20, 2022
·
5 min read
Business

Aquestive Therapeutics to Report Second Quarter 2022 Financial Results and Recent Business Highlights on August 2 and Host Conference Call on August 3 at 8:00 a.m. ET

Aquestive Therapeutics, Inc. today announced that it will report results for second quarter ended June 30, 2022, and provide an update on recent developments in its business after market close on Tuesday, August 2, 2022.

July 20, 2022
·
6 min read
Genetown

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

Rhythm Pharmaceuticals, Inc. today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and Haute Autorité de santé (HAS) have granted pre-marketing authorization AP1 (autorisation d’accès précoce - early access authorization),

July 20, 2022
·
9 min read
Deals

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech, Inc. today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement.

July 20, 2022
·
1 min read
Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead

Qu Biologics Inc. is pleased to announce it received clearance (No Objection Letter) from Health Canada to proceed with a randomized placebo-controlled clinical trial of QBKPN.

July 20, 2022
·
4 min read
Business

DLH to Announce Fiscal 2022 Third Quarter Financial Results

DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, will release financial results for its fiscal third quarter ended June 30, 2022 on August 2, 2022 after the market closes.

July 20, 2022
·
1 min read